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A B S T R A C T
In the 1980s particular endogenous metabolites of progesterone and of deoxycorticosterone were revealed to be
potent, eﬃcacious, positive allosteric modulators (PAMs) of the GABAA receptor (GABAAR). These reports were
followed by the discovery that such steroids may be synthesised not only in peripheral endocrine glands, but
locally in the central nervous system (CNS), to potentially act as paracrine, or autocrine “neurosteroid” mes-
sengers, thereby ﬁne tuning neuronal inhibition. These discoveries triggered enthusiasm to elucidate the phy-
siological role of such neurosteroids and explore whether their levels may be perturbed in particular psychiatric
and neurological disorders. In preclinical studies the GABAAR-active steroids were shown to exhibit anxiolytic,
anticonvulsant, analgesic and sedative properties and at relatively high doses to induce a state of general an-
aesthesia. Collectively, these ﬁndings encouraged eﬀorts to investigate the therapeutic potential of neurosteroids
and related synthetic analogues. However, following over 30 years of investigation, realising their possible
medical potential has proved challenging. The recent FDA approval for the natural neurosteroid allopregna-
nolone (brexanolone) to treat postpartum depression (PPD) should trigger renewed enthusiasm for neurosteroid
research. Here we focus on the inﬂuence of neuroactive steroids on GABA-ergic signalling and on the challenges
faced in developing such steroids as anaesthetics, sedatives, analgesics, anticonvulsants, antidepressants and as
treatments for neurodegenerative disorders.
1. Introduction
Almost 80 years ago Hans Selye demonstrated that particular
pregnane steroids can induce rapid sedation and a state of un-
consciousness (Selye, 1941). Approximately 40 years elapsed before a
viable molecular mechanism emerged to explain these rapid beha-
vioural eﬀects. Electrophysiological studies revealed the intravenous
synthetic steroidal general anesthetic alphaxalone (5α-pregnane-3α-ol-
11, 20-dione) to enhance the inhibitory eﬀects of GABA in guinea pig
olfactory cortex (Scholﬁeld, 1980) and in cat spinal cord neurons
(Lodge and Anis, 1984). Extracellular recordings in the rat cuneate
nucleus demonstrated alphaxalone to potently enhance responses
mediated by GABAA receptor (GABAAR) agonists (Harrison and
Simmonds, 1984). Supporting the GABAAR as a locus for the beha-
vioural eﬀect, betaxalone, a 3β-ol isomer of alphaxalone, had no eﬀect
on GABAARs and was behaviourally inert (Harrison and Simmonds,
1984). In their seminal paper they recalled that alphaxalone was
structurally related to certain endogenous pregnane steroids, raising the
prospect that the activity of the major inhibitory receptor in the
mammalian central nervous system (CNS), the GABAAR, may be subject
to physiological, or pathophysiological regulation (Harrison and
Simmonds, 1984). In conﬁrmation, subsequent electrophysiological
and radioligand binding approaches revealed particular metabolites of
progesterone (e.g., 5α-pregnan-3α-ol-20-one, also known as allo-
pregnanolone and now brexanolone) and of deoxycorticosterone (5α-
pregnan-3α, 21-diol-20-one, [5α-THDOC]) to also be highly eﬃcacious,
stereoselective, positive allosteric modulators (PAMs) of the GABAAR at
nM concentrations (Majewska et al., 1986; Barker et al., 1987;
Callachan et al., 1987; Cottrell et al., 1987; Gee et al., 1988; Peters
et al., 1988). Radioligand binding and electrophysiological studies es-
tablished that the GABA facilitatory actions of these steroids were not
mediated by binding to the proposed benzodiazepine site on the GA-
BAAR (Harrison and Simmonds, 1984; Cottrell et al., 1987; Gee et al.,
1988). In common with barbiturates, these steroids promoted the open
conducting state of the GABAAR associated anion channel, thereby
enhancing the actions of GABA and at higher concentrations, they di-
rectly activated the receptor (Majewska et al., 1986; Barker et al., 1987;
Callachan et al., 1987; Cottrell et al., 1987; Peters et al., 1988), leading
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T
to their description as “barbiturate-like” modulators (Harrison and
Simmonds, 1984 Majewska et al., 1986), although subsequently bar-
biturate/steroid interaction studies implied these GABAAR modulators
acted via distinct sites (Cottrell et al., 1987; Gee et al., 1988; Peters
et al., 1988). The potency and stereoselectivity of their actions sug-
gested involvement of a high aﬃnity steroid binding site located on the
GABAAR. However, the apparent aﬃnity derived from functional stu-
dies may be misleading as these steroids are highly lipophilic, causing
their accumulation to relatively high local concentrations in the
membrane i.e. in close apposition to a proposed transmembrane binding
site for the steroid on the GABAAR protein (Hosie et al., 2006; Chisari
et al., 2010).
In this review we use the term neurosteroid for endogenous steroids
synthesised in the CNS and the term neuroactive steroid for exogenous
GABAAR-active steroids.
2. Neuroactive steroids and GABAAR subtypes
The GABAAR is a member of the cys-loop transmitter-gated ion
channel family and is composed of ﬁve transmembrane crossing sub-
units. Studies in the late 1980s and early 1990s revealed an unexpected
diversity of GABAAR subunits (α1-6, β1-3, γ1-3, δ, ε, θ, π and ρ1-3), a
repertoire supporting the expression of ∼20–30 subtypes of GABAAR
(Olsen and Sieghart, 2009), that exhibit a distinct expression pattern
within the mammalian CNS. The majority of GABAARs are composed of
two α subunits, two β subunits and a γ subunit (predominantly, but not
exclusively the γ2 subunit). For some receptors the δ subunit (δ-GA-
BAARs) replaces the γ subunit. The GABAAR subunit composition in-
ﬂuences i) where in the CNS the receptors are expressed and their
subcellular location within a neuron e.g. synaptic vs extra/peri-synaptic
expression ii) the biophysical properties of the receptor, including rates
of deactivation, desensitization, and GABA aﬃnity iii) the eﬀect of
enzymes such as kinases and phosphatases upon receptor function and
expression), and iv) receptor pharmacology (Jacob et al., 2008; Olsen
and Sieghart, 2008; Fritschy and Panzanelli, 2014; Nakamura et al.,
2015).
In common with established PAMs of the GABAAR (e.g. diazepam),
neuroactive steroids exhibit anxiolytic, analgesic, anticonvulsant and
sedative eﬀects, but additionally at greater doses they induce a state of
general anaesthesia (Belelli and Lambert, 2005; Reddy and Estes,
2016). Although such steroids are highly selective PAMs of the GA-
BAAR, they exhibit only limited speciﬁcity for particular GABAAR iso-
forms (Belelli et al., 2009 Brickley and Mody, 2012). A possible ex-
ception are δ-GABAARs, where neurosteroids appear highly eﬃcacious,
although this apparent selectivity is probably secondary to the limited
eﬃcacy of GABA acting at δ-GABAARs (Brickley and Mody, 2012).
Table 1 utilises the voltage-clamp technique to compare the GABAAR
enhancing eﬀects of allopregnanolone, with structurally related syn-
thetic steroids across representatives of synaptic and extrasynaptic
GABAARs. In agreement with previous studies (Belelli et al., 2009
Brickley and Mody, 2012) inspection of Table 1 reveals little GABAAR
isoform speciﬁcity of these steroids. Given this GABAAR promiscuity a
key question concerns the identiﬁcation of the GABAAR subtypes that
mediate the behavioural repertoire neurosteroids. Experiments with
“knock-in” mice genetically engineered to express diazepam-insensitive
and etomidate-insensitive GABAARs have revealed components of their
behavioural eﬀects to be mediated by particular GABAARs (Rudolph
and Knoﬂach, 2011). Key transmembrane amino acids have been
identiﬁed that impair neurosteroid modulation of GABAARs, permitting
equivalent mouse behavioural studies, although to date there has not
been a comprehensive behavioural proﬁle of such mice (Newman et al.,
2016). In the absence of such studies, components of the behavioural
eﬀects neuroactive steroids may exhibit a similar receptor proﬁle to
those of other GABAAR modulators. However, whereas the eﬀects of
diazepam are mediated by enhancing the eﬀects of GABA at γ-GA-
BAARs, importantly neurosteroids additionally act as PAMs of δ-GA-
BAARs. Indeed, behavioural studies of mice with deletion of the genes
encoding for the δ subunit and the α4 subunit (often partnered with the
δ subunit) are proving instructive (see below).
Receptors incorporating the γ2 subunit, are primarily, although not
exclusively, expressed within inhibitory synapses, where they mediate
fast phasic responses (under voltage-clamp conditions recorded as in-
hibitory postsynaptic currents [IPSCs]) upon activation by the neurally-
evoked vesicular release of GABA (Farrant and Nusser, 2005; Brickley
and Mody, 2012). In common, both benzodiazepines such as diazepam
and neuroactive steroids prolong the IPSC duration, thereby enhancing
phasic inhibition. Certain neurons (e.g. hippocampal dentate gyrus
granule cells [DGGCs]; thalamocortical ventrobasal [VB] neurons) ad-
ditionally express neurosteroid-sensitive δ-GABAARs (Brickley and
Mody, 2012). These receptors are insensitive to benzodiazepines and
are predominantly expressed out with the inhibitory synapse in peri-
synaptic, or extrasynaptic locations (Brickley and Mody, 2012). In these
neurons extrasynaptic δ-GABAARs mediate a tonic, persistent current,
either in response to low ambient levels of GABA, or due to spontaneous
gating of the receptor-channel complex (Brickley and Mody, 2012;
Wlodarczyk et al., 2013). Neuroactive steroids, in common with GA-
BAAR-active general anaesthetics, such as etomidate and propofol, will
interact with synaptic γ2-GABAARs to prolong the duration of phasic
inhibition, but additionally with extrasynaptic δ-GABAARs to increase
tonic inhibition (Stell et al., 2003; Belelli and Lambert, 2005; Peden
et al., 2008; Brickley and Mody, 2012) – Fig. 1. By contrast, benzo-
diazepines will primarily inﬂuence phasic inhibition, although certain
neurons do express benzodiazepine-sensitive γ2 subunit containing
GABAARs (e.g. α5βγ2), that mediate a tonic conductance (Caraiscos
et al., 2004);
Considering how neurons respond during physiological rates of
presynaptic stimulation, this division of fast phasic and tonic inhibition
may be an over simpliﬁcation. For example thalamocortical VB neurons
Abbreviations
Ad Alzheimer's disease
allopregnanolone 5α-pregnan-3α-ol-20-one
CNS central nervous system
DGGCs dentate gyrus granule cells
EEG electroencephalogram
FDA food and drug administration
GABAAR GABAA receptor
HPA hypothalamus, pituitary, adrenal axis
IPSC inhibitory postsynaptic current
im intramuscular
iv intravenous
MOA mechanism of action
nRT nucleus reticularis
NREM non rapid eye movement
ORG ORG OD02-0
PAM positive allosteric modulator
PD pharmacodynamic
pGPCR progesterone G-protein coupled receptor
PK pharmacokinetic
PKA protein kinase A
PKC protein kinase C
po oral administration
PPD postpartum depression
REM rapid eye movement
SE status epilepticus
VB ventrobasal
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are innervated by GABA-ergic nucleus reticularis (nRT) neurons.
Murine VB neurons express synaptic (α1β2γ2) and extrasynaptic
(α4β2δ) GABAARs, that mediate fast phasic and tonic inhibition re-
spectively (Peden et al., 2008; Herd et al., 2013). During drowsiness
and non-rapid eye movement (NREM) sleep these presynaptic nRT
neurons ﬁre with high frequency bursts, consequently releasing sub-
stantial amounts of GABA onto VB neurons, which in addition to en-
gaging synaptic GABAARs, spills over from the synapse to activate peri-
and extrasynaptic GABAARs. Under voltage-clamp this spillover GABA
results in a greatly prolonged IPSC. The slow component of the IPSC is
absent in α4−/− mice and is prolonged by DS2, a δ-GABAAR-selective
PAM (Herd et al., 2013), conﬁrming it to be mediated by activation of
extrasynaptic GABAARs (α4β2δ). For VB neurons allopregnanolone and
related GABAAR-active steroids greatly prolong fast phasic inhibition
and increase the tonic current (Brown et al., 2015) – Fig. 1. Although
the eﬀects of neurosteroids on this spillover component of the IPSC
remains to be determined, it is probable that allopregnanolone, in
common with DS2 and etomidate (an intravenous general anesthetic),
will greatly prolong such events (Herd et al., 2013, 2014). By contrast,
benzodiazepines would be inert in this respect, causing only a relatively
modest prolongation via the synaptic (α1β2γ2) component of the IPSC
(Peden et al., 2008). Therefore, in some neurons the neurosteroid eﬀect
upon neural inhibition may be considerably greater than that of ben-
zodiazepines (Weir et al., 2017).
A recent report highlights a further important, but indirect action of
neurosteroids upon tonic inhibition (Parakala et al., 2019). In addition
to binding to GABAARs, certain steroids, including allopregnanolone
and progesterone activate a family of progesterone G-protein coupled
receptors (p-GPCRs) located on the membrane surface (Pang et al.,
2013; Schumacher et al., 2014; Parakala et al., 2019). The steroid ORG
OD 02-0 (ORG) selectively activates these p-GPCRs, with no eﬀect upon
nuclear progesterone receptors and importantly, in contrast to allo-
pregnanolone, has no direct interaction with GABAARs (Parakala et al.,
2019). Activation of p-GPCRs by ORG has no immediate eﬀect upon
phasic, or tonic inhibition of dentate granule neurons. However, pro-
longed p-GPCR activation by this steroid produced a delayed, selective
and sustained increase of the tonic current, due to an increased cell
surface expression of extrasynaptic GABAARs, with no eﬀect on phasic
inhibition (Parakala et al., 2019). This metabotropic eﬀect of ORG and
allopregnanolone on GABAAR traﬃcking resulted from phosphorylation
of particular serine residues of the GABAAR β3 subunit via an in-
volvement of PKA and PKC (Parakala et al., 2019). Importantly, al-
though the neuroactive steroid ganaxolone acutely increased the tonic
current of hippocampal DGGNs, in contrast to allopregnanolone it did
not produce a sustained enhancement of this conductance (Modgil
et al., 2017).
In summary, allopregnanolone interacts directly with GABAARs to
acutely prolong phasic and enhance tonic inhibition, but may exert an
additional, metabotropic eﬀect to increase tonic inhibition on a slower
time scale, by selectively inﬂuencing extrasynaptic GABAAR traﬃcking.
This form of sustained GABAAR plasticity may be important in under-
standing the therapeutic and physiological eﬀects of allopregnanolone.
In particular, it may underpin behavioural eﬀects of allopregnanolone
that remain following elimination of the steroid from the CNS. As
highlighted by the diﬀerential proﬁle of ganaxolone (Modgil et al.,
2017), for future drug discovery programs, consideration of the activity
of synthetic steroids upon the family of p-GPCRs may be warranted, in
addition to the current focus on their direct interaction with the GA-
BAAR. In certain neurons, including DGGNs, the extrasynaptic δ-GA-
BAARs incorporate the β2 subunit (e.g. α4β2δ) – (Peden et al., 2008;
Herd et al., 2008). It will be of interest to explore if this metabotropic
eﬀect extends to such receptors (see Modgil et al., 2017).
We will now consider attempts to develop neuroactive steroids as
novel therapeutics, focussing primarily on indications where the
GABAAR is the likely site of action and where possible clinical ﬁndings
are available for evaluation.
3. Developing clinical applications of neuroactive steroids
3.1. General anesthetics
The initial clinical use of neuroactive steroids was as general an-
aesthetics. Following the discovery that progesterone exhibits both se-
dative and anticonvulsant eﬃcacy in preclinical models (Selye, 1941),
it was tested in humans intravenously (iv.) at 500mg, a dose that
produced an anesthetic eﬀect (Merryman et al., 1954). This observation
provided the impetus to examine the basis for this eﬀect of proges-
terone and whether it had applications in developing new medicines.
Based on pioneering work by Syntex on hypnotic steroids (Gyermek
et al., 1968), in the 1970s Glaxo developed “Althesin” a combination of
the steroids alphaxolone and alfadalone (Child et al., 1971). These
steroids are analogues of allopregnanolone, the former has an 11-car-
bonyl substitution and the latter an 11-carbonyl, 21-hydroxyl sub-
stitution. As described (Introduction), alphaxalone is an eﬃcacious
GABAAR PAM. Clinically, Althesin was tested as a potential iv. induc-
tion agent undergoing clinical trials in the United States in the 1970s,
but did not receive FDA approval for this application, although it was
approved by regulatory agencies in Europe.
Althesin was formulated in a surfactant polyethylated castor oil
(Cremophor). The attractive properties of Althesin, that distinguished it
from other induction agents, were a lack of adverse cardiovascular, or
respiratory eﬀects, coupled with a limited post-recovery hangover due
to a short half-life (Towler et al., 1982). However, Althesin caused
anaphylaxis, resulting in withdrawal from human use, although it is
used in veterinary practice (Barletta, 2019). The anaphylaxis was
caused by histamine release induced by Cremophor and not the active
components of Althesin (Johnson et al., 2011). An additional adverse
eﬀect of Althesin was hyperexcitability observed during induction and
seizure activity during recovery (Towler et al., 1982). Minaxolone, a
2β-ethoxy, 11α-dimethylamino substituted analogue of allopregnano-
lone was also developed, but never marketed (Kharasch and Hollmann,
2015). Organon improved upon the poor solubility by creating a series
of water-soluble neuroactive steroids with anesthetic properties, which
were highly eﬃcacious GABAAR PAMs (Hill-Venning et al., 1996;
Fig. 1. SAGE-217 greatly enhances both phasic and tonic inhibition GABAAR in
mouse thalamic VB neurons. A) GABAAR mIPSCs recorded at −70 mV from a
representative VB neuron of a neonatal (P21) mouse horizontal slice before
(Control, black trace) and following 10min of SAGE 217 (1 μM, green trace).
The mIPSCs appear as downward deﬂections from the baseline. Note the pro-
longation of the mIPSC decay by SAGE 217 and the simultaneous increase of the
baseline noise. B) An all-points histogram of the holding current from the same
recording depicted in A) under control conditions (black), following SAGE 217
(1 μM, green) and co-application of bicuculline (20 μM, grey). Note the large
inward shift in the holding current after SAGE 217 (1 μM) and the reversal
beyond the control holding current following bicuculline (20 μM), revealing a
clear GABAAR tonic conductance. See Brown et al., 2015 for recording condi-
tions. (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the Web version of this article.)
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Sneyd et al., 1997). These steroids included two candidates (Org-20599
and Org-21465) based on morpholinyl substitutions at the 2β-position
on the steroid A ring and were advanced into clinical trials. In common
with Althesin, their excitatory actions led to discontinuation of the
trials (Gasior et al., 1999). Interestingly, a reformulated version of al-
phaxalone (Phaxan), which uses a cyclodextrin as a carrier, is currently
in clinical development by Drawbridge Pharmaceuticals. This re-
formulation potentially eliminates the toxic eﬀects of the original
Cremophor formulation, but whether post-recovery excitability can be
mitigated remains to be established.
The discovery of the GABA-modulatory eﬀects of allopregnanolone
encouraged exploring additional medical applications, common to es-
tablished GABAAR modulators e.g. benzodiazepines.
3.2. Sedatives
Satisfactory sleep is crucial for physical and mental health (Krause
et al., 2017). Various neuropsychiatric disorders including depression
and schizophrenia are accompanied by disrupted sleep architecture.
Benzodiazepines and zolpidem are widely prescribed for sleep dis-
orders, but their side eﬀects, including tolerance and withdrawal, make
them far from ideal (Waﬀord and Ebert, 2008). Investigations of se-
dative applications of the allopregnanolone-related steroids have been
sporadic, despite sedation being their most apparent behavioural eﬀect.
Clinical trials of Althesin and alphaxalone revealed sedative eﬀects
(Ramsay et al., 1974; Stewart et al., 1983). Neuroactive steroids have
desirable attributes at sedative doses including a short duration of ac-
tion, no hangover, no eﬀects on sleep architecture, limited eﬀects on
cognition and an absence of cardiovascular and respiratory depression
(Towler et al., 1982).
Although the neuroactive steroids were described as “barbiturate
like” (Harrison and Simmonds, 1984; Majewska et al., 1986) they were
subsequently shown to act upon a distinct site on the GABAAR (In-
troduction). This ﬁnding opened a path to patent (US patent No.
5,120,723) the use this novel site on the GABAAR, by Gee and collea-
gues for the treatment of CNS disorders amenable to modulation by
neuroactive steroids. This patent and others led to the development of
synthetic neuroactive steroids related to allopregnanolone as drug
candidates by CoCensys (Belelli et al., 1990; McNeil et al., 1992; Gee
et al., 1995). They developed several orally bioavailable steroids for
evaluation as sedative-hypnotics (Edgar et al., 1997; Vanover et al.,
2001). In particular, CCD-3693, was more eﬃcacious than benzodia-
zepines in promoting NREM sleep. In rats CCD-3693 did not interfere
with rapid eye movement (REM) sleep and was more selective in re-
ducing electroencephalogram (EEG) wakefulness, with less impairment
of locomotor activity during waking than triazolam, or zolpidem (Edgar
et al., 1997). In contrast to the benzodiazepines, neuroactive steroids do
not produce a distinct “rebound” wakefulness following their NREM
sleep-promoting eﬀect. CCD-3693 was progressed into clinical devel-
opment by CoCensys in collaboration with Searle in the 1990s, where it
demonstrated similar properties on human sleep. Although CCD-3693
had a superior pharmacodynamic (PD) proﬁle to that of benzodiaze-
pines, it was not developed then because of pharmacoeconomic con-
siderations.
Regarding mechanism, the sedative eﬀects of the benzodiazepines
are primarily mediated by α1βγ2 GABAARs (Waﬀord and Ebert, 2008;
Rudolph and Knoﬂach, 2011) and neuroactive steroids are eﬀective
PAMs of such receptors (Table 1; Fig. 1). However, the sleep times in-
duced by allopregnanolone and alphaxalone are reduced in δ−/- sub-
unit mice, implicating extrasynaptic δ-GABAARs (Mihalek et al., 1999).
Similarly, the sedative eﬀects of gaboxadol, a δ-GABAAR-selective
agonist (Belelli et al., 2005) are impaired in δ−/- mice (Boehm et al.,
2006; Waﬀord and Ebert, 2008; Herd et al., 2009). Although these
studies identify a credible target for developing steroid based sedatives,
their poor oral bioavailability remains a major impediment.
3.3. Anticonvulsant
The demonstration that a single iv. infusion of Althesin suppressed
seizures in 7 of 9 patients with status epilepticus (SE) provided the ﬁrst
clinical evidence that steroids related to allopregnanolone have antic-
onvulsant activity (Munari et al., 1979). Clearly a logical and obvious
indication for allopregnanolone was epilepsy. In support, allopregna-
nolone exhibits anticonvulsant eﬃcacy in a number of preclinical
models of seizures (Belelli et al., 1989; Luntz-Leybman et al., 1990;
Kokate et al., 1994, 1996; Devaud et al., 1995; Kaminski et al., 2004;
Reddy and Rogawski, 2012; Wu and Burnham, 2018). However, neither
Althesin, nor allopregnanolone, were viable as orally active antic-
onvulsants, having plasma half-lives of< 1 h, limited solubility and
oral bioavailability (Irwin et al., 2015). Side-stepping this impediment,
a recent study described the successful treatment of two patients suf-
fering from super-refractory SE following a two day continuous infusion
with allopregnanolone (Vaitkevicius et al., 2017). Recently Sage
Therapeutics, Inc. (Sage) took an i.v. formulation of allopregnanolone
(brexanolone) into clinical testing for the treatment of drug refractory
SE. The preparation, designated SAGE-547, showed promise in phase II
trials, but failed to meet clinical endpoints in phase III (Rosenthal et al.,
2017; Cox, 2017). Why SAGE-547 failed in phase III is not known.
Perhaps the heterogeneous aetiology of SE undermines a response to
the drug alone, or poor solubility prevented an optimal concentration
from being achieved in the formulation used. Alternatively, a sustained
allopregnanolone infusion may cause rapid PD tolerance (Turkmen
et al., 2011). The clinical eﬃcacy of allopregnanolone in large scale
trials remains to be established in epilepsy, despite activity in pre-
clinical models, or the anecdotal evidence of clinical activity of Althesin
and other neuroactive steroids (Munari et al., 1979).
Ganaxolone, a synthetic analogue of allopregnanolone, was syn-
thesised by CoCensys in the early 1990s to improve oral bioavailability,
prevent in vivo conversion to progesterone and to increase the biological
half-life (Carter et al., 1997). The introduction of a 3β-methyl group in
ganaxolone signiﬁcantly improved half-life, while retaining the GA-
BAAR eﬃcacy of allopregnanolone (Carter et al., 1997) –Table 1. This
steroid was advanced by CoCensys into clinical trials in 1991 and
showed promise as a potential antiepileptic (Reddy and Estes, 2016;
Sperling et al., 2017). Ganaxolone was redirected for the treatment of
acute migraine based on an uncertain rationale, but failed to demon-
strate eﬃcacy in phase II trials. Despite this costly detour, ganaxolone is
currently under clinical development by Marinus Pharmaceuticals for
treatment of various indications directed at seizure disorders, including
cyclin-dependent kinase-like 5 deﬁciency disorder, protocadherin 19-
related epilepsy and refractory SE (NCT03572933, NCT03865732,
NCT03350035).
Recently, a series of novel (WO 2013/019711 A2) allopregnano-
lone-related steroids were designed to improve the aqueous solubility,
bioavailability and side-eﬀect proﬁle of established neuroactive steroids
and tested for antiepileptic activity (Hogenkamp et al., 2014). These
17β-heteroaryl steroids are represented by UCI-50027, the prototype in
this series, 3-[3α-hydroxy-3β-methyl-5α-androstan-17β-yl]-5-(hydro-
xymethyl)isoxazole. UCI-50027 is an orally active anticonvulsant and
anxiolytic, which overcomes the general dosing limitations of other
neuroactive steroids. UCI-50027 has an improved preclinical pharma-
cokinetic (PK) and side-eﬀect proﬁle, which makes it more potent and
tolerable as an anxiolytic and anticonvulsant than ganaxolone. For
example, UCI-50027 has a greater anticonvulsant/anxiolytic ther-
apeutic index than ganaxolone in rodent seizure models. Ganaxolone
and UCI-50027 produce a robust enhancement of submaximal GABA-
evoked currents in oocytes expressing human recombinant α1β2γ2L
and α4β3δ GABAARs (Table 1). Both compounds are potent modulators
of α2β1γ2L GABAARs, but whereas ganaxolone greatly enhanced the
response to GABA irrespective of the β subunit isoform, UCI-50027
produced only a relatively modest maximum modulation of α2β1γ2L,
c.f. α2β2γ2L GABAARs (Table 1). The diﬀerential inﬂuence of the β
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subunit appeared selective for α2, but not the α1 subunit-containing
GABAAR (Table 1). This reduced activity at the β1-subunit subtype may
diminish the propensity to cause sedative/ataxic side eﬀects in vivo at
therapeutically relevant doses (Gee et al., 2010; Hogenkamp et al.,
2014), although note the sedative eﬀects of etomidate are mediated by
GABAARs incorporating the β2-subunit (Reynolds et al., 2003).
Preclinical and clinical evidence suggests that allopregnanolone and
related analogues should be useful in the treatment of various epi-
lepsies, but to date none have received regulatory approval. Perhaps a
more targeted approach, that requires a precise matching of the un-
derlying pathophysiology of the various seizure disorders with the
mechanism of action (MOA) of neurosteroids, may be a prerequisite for
success. In that regard, numerous genetic mutations of GABAAR sub-
units, implying impairments to phasic and tonic inhibition, associate
with particular epilepsies, including mutations of the δ-subunit
(Macdonald et al., 2010). Some clinical anticonvulsants increase am-
bient levels of GABA, suggesting manipulations to inﬂuence tonic in-
hibition may be beneﬁcial in certain conditions (Brickley and Mody,
2012). However, note that enhancement of tonic inhibition in models of
absence epilepsy aggravates the condition by promoting thalamic burst
ﬁring (Cope et al., 2009; Errington et al., 2011).
3.4. Post-partum depression (PPD)
Blockade of neurosteroid production by inhibition of 5α-reductase
with ﬁnasteride increases depression-like behaviors in experimental
animal models (Walf et al., 2006; Beckley and Finn, 2007) and in some
men treated for male pattern hair loss i.e. “ﬁnasteride syndrome” (Locci
and Pinna, 2017; Melcangi et al., 2017). Allopregnanolone levels are
negatively correlated with depression-like behaviors (Walf et al., 2006).
Moreover, in humans antidepressant treatments increase allopregna-
nolone levels, which may be an integral component of their therapeutic
eﬀect (Romeo et al., 1998; Uzunova et al., 1998; Schule et al., 2007,
2011; Locci and Pinna, 2017). These ﬁndings are consistent with the
documented role of the hypothalamus, pituitary, adrenal axis (HPA)
dysfunction in the aetiology of depression (Lupien et al., 2009) and the
dynamic regulation of neurosteroid levels in response to stressful ex-
periences (Purdy et al., 1991; Tomaselli and Vallee, 2019) to inﬂuence
HPA axis activity (Patchev et al., 1994; Gunn et al., 2015).
Mirroring changes in progesterone, allopregnanolone levels rise
steadily through pregnancy until shortly before childbirth, when they
begin to fall, with a steep decline occurring immediately after birth
(Luisi et al., 2000; Gilbert Evans et al., 2005; Paoletti et al., 2006: Locci
and Pinna, 2017). One hypothesis suggests enhanced allopregnanolone
levels during pregnancy may reduce expression of extrasynaptic α4βδ
GABAARs, which remain depressed among patients who develop PPD
(Maguire and Mody, 2008; Licheri et al., 2015; Osborne et al., 2017). In
support, homozygous (δ−/-) and heterozygous (δ+/-) mice, impaired in
their ability to decrease and upregulate δ-GABAAR expression during
pregnancy and postpartum respectively, developed depression-like and
abnormal maternal behaviors, resulting in reduced pup survival
(Maguire and Mody, 2008), although see Gunn et al. (2013). These
symptoms were reversed in the heterozygous δ+/- mouse by the δ-
GABAAR selective agonist gaboxadol (Maguire and Mody, 2008). If a
similar dysregulation of receptor dynamics postpartum occurs in PPD
then depressive symptoms may be exacerbated by ﬂuctuating allo-
pregnanolone levels and reduced δ-GABAAR expression.
Evidence relating perinatal mood and anxiety symptoms with ab-
solute levels of allopregnanolone has been equivocal, especially in
larger population studies. Reduced allopregnanolone levels are in-
versely correlated with depression scores in women during late preg-
nancy (Hellgren et al., 2014), but not in the second trimester (Hellgren
et al., 2017). Interestingly, in this study a polymorphism in a gene in-
volved in allopregnanolone synthesis, aldo-keto reductase family 1,
which results in reduced allopregnanolone levels, was associated with
an increase in depression scores. In another study second trimester
cortisol, progesterone, pregnanolone and allopregnanolone levels were
correlated with negative emotional symptoms (Crowley et al., 2016).
Additional investigations demonstrated altered levels of GABA and
neurosteroids in association with PPD (Deligiannidis et al., 2016). In
contrast, mean allopregnanolone levels at 6 weeks postpartum in over
1500 ethnically diverse women showed no diﬀerence between healthy
postpartum women and those with PPD (Guintivano et al., 2018). Low
second trimester allopregnanolone levels were reported to predict
subsequent PPD in a study of 60 pregnant women with mood disorders,
where each additional ng/ml of this steroid reduced the probability of
developing PPD by 63% (Osborne et al., 2017). However, there was no
correlation when based on third trimester levels, consistent with an-
other small study (Deligiannidis et al., 2013). It is not evident why le-
vels during the third trimester showed no association. Studies reporting
an association not with concurrent, but with subsequent symptoms,
suggest that interactions with other systems, or other disease modifying
changes (e.g., receptor plasticity, gene transcription/expression, or
changes to rate-limiting enzymes - Agis-Balboa et al., 2014) and other
pleiotropic events may contribute to the complex interactions between
allopregnanolone and perinatal symptoms.
Regardless, recent treatment trials of the synthetic iv. formulation of
allopregnanolone (brexanolone), in phase III trials on PPD resulted in a
statistically signiﬁcant diﬀerence in remission rates between placebo
and two diﬀerent doses of brexanolone (Meltzer-Brody et al., 2018).
Although not new since CoCensys (U.S. patent No. 5,120,723, issued
1992) anticipated the use of allopregnanolone for PPD, Sage was
awarded breakthrough status and FDA approval for brexanolone as the
ﬁrst drug approved speciﬁcally for PPD. The steady-state plasma levels
of brexanolone based on the Cmax were in the 150–300 nM range during
treatment infusion of PPD, corresponding to half the human EC50 for
enhancement of α4β3δ GABAAR function by allopregnanolone (Brown
et al., 2002). This magnitude of GABAAR facilitation would presumably
be near maximal if the brain concentration is ×3 that in plasma, as
observed in rodents (Irwin et al., 2015). Sage has rediscovered Co-
Censys’ neuroactive steroids with a follow-on compound to brex-
anolone, SAGE-217, a synthetic orally-active allopregnanolone ana-
logue that is covered generically in CoCensys patents (U.S. 6,143,736
issued Nov. 7, 2000 and U.S. 6,277,838 issued Aug. 21, 2001). They
reported positive results with the compound in their phase II study
when tested at 30mg p.o. (once a day for 14 days). In common with
allopregnanolone, SAGE-217 is a potent PAM of recombinant receptors,
representative of both synaptic (α1/2β1/2γ2) and extrasynaptic
(α4β3δ) GABAARs (Table 1) – Martinez Botella et al. (2017). In
agreement with this proﬁle, for mouse thalamic VB neurons we ﬁnd
SAGE-217 (1 μM) to greatly prolong the duration of miniature in-
hibitory postsynaptic currents (mIPSCs) mediated by synaptic (α1β2γ2)
GABAARs and to enhance the tonic current mediated by extrasynaptic
(α4β2δ) GABAARs – Fig. 1.
Marinus is testing ganaxolone as an orally bioavailable treatment
for PPD (NCT03228394, NCT03460756) with preliminary ﬁndings re-
ported in the trade press as not meeting primary endpoints at an oral
(p.o) dose of 1175mg (once per day for 28 days). Given the similar
GABAAR proﬁle of these neuroactive steroids (Table 1) why is one
steroid clinically active and the other inert? For example are they dis-
tinguished by their ability to activate the metabotropic progesterone
receptor, leading to diﬀerences of δ-GABAAR traﬃcking (Modgil et al.,
2017; Parakala et al., 2019)? Alternatively, the answer may reside in
analysis of their pharmacokinetics, or other properties, revealed when
these results are reported in peer-reviewed literature.
The intriguing possibility that neuroactive steroids have wider ap-
plications in clinical depression beyond PPD is now under investigation
(Luscher and Mohler, 2019). A recent phase II study reported oral
SAGE-217 treatment for 14 days to be eﬀective in reducing depressive
symptoms in patients with moderate to severe major depressive dis-
order (Gunduz-Bruce et al., 2019). The main side eﬀects included diz-
ziness and somnolence/sedation, not surprising given the GABAAR
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proﬁle of this steroid (Table 1, Fig. 1).
If the apparent therapeutic eﬀect is due primarily to acute facilita-
tion of extrasynaptic δ-GABAAR function then other agents with a si-
milar activity proﬁle, may be useful in the treatment of PPD and other
depressive disorders. Note benzodiazepines, which have no activity at
δ-GABAARs, are not considered clinically useful in the treatment of
depression per se (Baldwin et al., 2013), whereas clinically available
drugs such propofol and etomidate, which in common with allo-
pregnanolone, acutely enhance both phasic and tonic inhibition may be
of interest (Belelli et al., 2005; Jia et al., 2007; Herd et al., 2013; Brown
et al., 2015). However, note compounds such as propofol are unlikely to
activate p-GPCRs to elicit a sustained eﬀect upon δ-GABAAR-mediated
tonic inhibition, distinguishing them from allopregnanolone (Abramian
et al., 2014; Parakala et al., 2019).
Finally, studies investigating the impact of depressive disorders on
not only levels of allopregnanolone, but on the steroid metabolome,
may prove instructive and identify additional steroid targets (Sharp
et al., 2018; Tomaselli and Vallee, 2019).
3.5. Analgesia
The thalamus is associated with the processing of nociceptive sig-
nals (Steriade and Deschenes, 1984; McCormick, 1992; Oliveras and
Montagne-Clavel, 1994). Thalamic sensory relay neurons receive
GABA-ergic projections from sensory nuclei and the thalamic reticular
nucleus (Steriade and Deschenes, 1984; McCormick, 1992). Micro-
injection of the GABAAR antagonist picrotoxin into the rat thalamic VB
complex results in “pain-like” behavior (Oliveras and Montagne-Clavel,
1994). As discussed (Section 2), electrophysiological and im-
munohistochemistry studies reveal mouse VB neurons to express neu-
rosteroid-sensitive synaptic (α1β2γ2) and extrasynaptic (α4β2δ) GA-
BAARs (Peden et al., 2008; Herd et al., 2013; Brown et al., 2015 –
Fig. 1). Allopregnanolone is active in numerous models of acute and
pathological pain states, with evidence of a neuroprotective eﬀect
(Kavaliers and Wiebe, 1987; Svensson et al., 2013; Borowicz et al.,
2011; Rey and Coirini, 2015). The antinociceptive eﬀects of allo-
pregnanolone and ganaxolone are impaired in the δ−/- mice (Mihalek
et al., 1999). The δ-GABAAR agonist gaboxadol is antinociceptive in
rodents and humans (Reyes-Vazquez and Dafny, 1983; Grognet et al.,
1983; Lindeburg et al., 1983; Kjaer and Nielsen, 1983), but analgesic
eﬃcacy is attenuated in the α4−/− mouse (Chandra et al., 2006).
Collectively, these studies implicate extrasynaptic α4βδ GABAARs in
mediating, or contributing to the antinociceptive eﬀects of neuroactive
steroids, possibly by enhancing thalamic burst ﬁring (Cheong et al.,
2008) and identify a putative target for the development of pain ther-
apeutics (Whissell et al., 2015). Clinically, allopregnanolone and re-
lated analogues have not been evaluated for activity in pain states. The
lack of reports on self-administration and tolerance to the analgesic
eﬀects of allopregnanolone related drugs, in contrast to opioids, makes
them worthy of consideration as analgesics.
3.6. Alzheimer's disease (AD) and neurodegenerative disorders
The role of allopregnanolone and related steroids in AD remains to
be established as to whether it has a causal contribution, or is an epi-
phenomenon of the disease. It may be important to distinguish between
the action of allopregnanolone as a PAM of the GABAAR versus actions
at other sites (e.g., pregnane X receptor, membrane bound p-GPCR –
Section 2). In preclinical AD models allopregnanolone promotes neu-
rogenesis, restores cognitive function and reduces pathology (Wang
et al., 2010; Irwin et al., 2014; Ratner et al., 2019). The levels of al-
lopregnanolone are reduced in the prefrontal cortex of AD patients
(Marx et al., 2006). Perhaps GABAAR actions may contribute to the
protective eﬀects of allopregnanolone on neurodegeneration in AD
models, but full eﬃcacy may require a broader scope of interactions.
However, the nature and extent of this contribution is unclear and may
be minimal since ganaxolone (up to 30mg/kg at 4 h post-injury) and
pregnanolone (20mg/kg) showed little eﬀect in a preclinical model of
cerebral hematoma, as measured by neurological and histological out-
comes up to 3 months post-hematoma (Lyden et al., 2000). Ad-
ditionally, progesterone failed to meet primary criteria in phase III
clinical trials for the treatment of moderate to severe traumatic brain
injury, although the contribution of allopregnanolone and related
steroids, is unknown (Wright et al., 2014; Skolnick et al., 2014).
Nevertheless, i.v. allopregnanolone has been tested in traumatic brain
injury with equivocal results (NCT01673828).
Given the short metabolic half-life and absence of any reported PK/
PD relationship at the GABAARs in various AD models of cognitive
deﬁcits, among the most compelling argument for its MOA is a pleio-
tropic eﬀect of allopregnanolone and related steroids, perhaps in-
cluding an action upon p-GPCRs to inﬂuence GABAAR expression
(Parakala et al., 2019, Section 2). Allopregnanolone is currently in
clinical trials for the treatment of mild cognitive impairment due to AD
(NCT02221622). It was reported to be safe and well-tolerated in the
2–16mg intramuscular (im.) range in a small blinded- and placebo-
controlled trial of 24 patients (both male and female, age 55 and
above), with mild cognitive impairment due to AD, or mild AD (Brinton
et al., 2018). In this study the CogState battery scores showed high
variability, with no signiﬁcant diﬀerences in cognitive measures be-
tween groups, though scores trended towards improvement with
treatment. Although anecdotal, MRI studies reported allopregnanolone
(4mg dose, intramuscular im.) to improve functional connectivity be-
tween the right parietal lobe and posterior cingulate cortex and to ex-
hibit a sustained eﬀect on hippocampal volume over the 3 weeks of
treatment (Brinton et al., 2018). These encouraging preliminary results
will require conﬁrmation by larger trials to determine the validity of the
drug target in AD. Interestingly, the acute administration of allo-
pregnanolone and other GABAAR-active steroids to healthy subjects
inhibits learning and memory function in a manner similar to the
benzodiazepines (Bruins Slot et al., 1999; Johansson et al., 2002).
3.7. Beyond neurosteroids: non-steroid compounds selectively targeting
α4βδ GABAAR subtypes
The clinical development of ganaxolone and allopregnanolone as
drugs has relied on the use of patented formulations, which is driven by
their poor physicochemical properties e.g. high lipophilicity (logP),
which inﬂuences the bioavailability of the steroid. This major short-
coming is due to the intrinsic requirement of the androstane, or preg-
nane steroid core structure for eﬃcacy (Hogenkamp et al., 2007). Al-
though care is warranted regarding the interpretation of mouse gene
deletion studies, the impaired behavioural eﬃcacy of neuroactive
steroids for either δ−/- or α4−/− mice identify extrasynaptic α4βδ
GABAARs as a target of interest in exploring the therapeutic potential of
neuroactive steroids. As discussed (Section 2), the discovery that cer-
tain neuroactive steroids additionally activate p-GPCRs (Pang et al.,
2013), leading to increased cell surface expression of δ-GABAARs
(Parakala et al., 2019) may warrant determining the eﬃcacy of novel
steroids upon this target, in addition to proﬁling their eﬀect upon
GABAAR isoforms.
Alternatively, structural chemotypes with PAM activity at α4βδ
GABAARs, but improved physicochemical properties can be evaluated
for indications for which neurosteroids have potential and demon-
strated therapeutic utility. Currently there are few non-steroidal, small
molecules that are selective for δ-GABAAR subtypes. DS2 is a highly
selective PAM for extrasynaptic δ-GABAARs, exhibiting no activity on
synaptic GABAARs, but it has poor CNS penetration and was not dosed
orally for pharmacological evaluation (Waﬀord et al., 2009; Jensen
et al., 2013). Nevertheless, DS2 is reported to improve recovery in a
mouse model of stroke by an anti-inﬂammatory mechanism (Neumann
et al., 2019). AA29504 (Hoestgaard-Jensen et al., 2010), has a favor-
able ratio of brain to plasma levels, but was not dosed orally, nor is it a
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pure PAM since it also has direct agonist activity (Vardya et al., 2012).
Furthermore, as a carbamate, AA29504 may be too unstable to be ab-
sorbed through the gut after oral dosing. The selective δ-GABAAR
agonist gaboxadol (in clinical development by Ovid Pharmaceuticals
for treatment of Angelman and Fragile X syndromes) may worthy of
consideration (Brown et al., 2002). However, the activity of δ-GABAAR
PAMs are governed in part by physiological ﬁring patterns (Section 2),
whereas this is presumably less so for direct agonists such as gaboxadol
(Herd et al., 2013; Weir et al., 2017).
The non-steroidal small molecules 2–261 and 2–329 (Table 1), act
as GABAAR PAMs via a binding site distinct from that of neurosteroids,
or benzodiazepines (Gee et al., 2010). They compare favorably to the
neurosteroids, including those currently in clinical development, in
terms of potency, eﬃcacy and selectivity for GABAAR subtypes in-
cluding the α4β3δ isoform (Table 1). They display unique pharmaco-
logical properties, which can be readily manipulated through their
novel SAR to produce desirable side eﬀect/safety proﬁles based on
GABAAR receptor subunit-selectivity. For example, the orally bioavail-
able prototype, 2–261, retains anxiolytic activity without ataxia, cog-
nitive impairment, ethanol potentiation, rewarding eﬀects (linked to
addiction), tolerance, or withdrawal (Gee et al., 2010; Yoshimura et al.,
2014). Furthermore, in rodents 2–261 has a neurosteroid-like proﬁle in
blocking electrical- and chemical-kindled seizures and organopho-
sphate-induced SE, and exhibits activity in chronic pain (Reddy et al.,
2018; Johnstone et al., 2019a, b). Thus, retention of therapeutically
desirable eﬀects of the GABAAR-active steroids, but not their side ef-
fects, is clearly advantageous. The freedom to operate in the patent
space provided by small molecules yields a more ﬂexible approach to
drug development, that builds upon the extensive body of knowledge
accumulated during the last three decades on neuroactive steroids and
GABAARs, but avoids their poor physicochemical properties and the
prior art of the neurosteroid patent mineﬁeld.
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